FTase

For general laboratory use.

Envio: shipped on dry ice

Condições de armazenamento: store at -80 °C
avoid freeze/thaw cycles

Validade: 12 months

Peso molecular: α: 44 kDa, β: 49 kDa

Número de acesso: Q04631 / Q02293

Número de acesso: Q04631 / Q02293

Pureza: > 90 % (SDS-PAGE)

Forma: liquid (Supplied in 25 mM HEPES pH 7.2, 40 mM NaCl, 1 mM TCEP and 10 μM ZnSO4)

Atividade: 1 pmol of FTase will transfer 1 pmol of farnesyl to H-Ras in 15 min at 37°C.

Descrição:
FTase catalyzes the transfer of the farnesyl group from farnesyl diphosphate to proteins containing a C-terminal CaaX motif, where 'C' is a conserved cysteine that is the site of farnesyl modification, 'a' is usually an aliphatic amino acid, and 'X' is methionine, serine, glutamine, or alanine.

Referências selecionadas:
Lackner et al. (2005) Chemical genetics indentifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell. 7:325.

Zimmerman et al. (1998) High-level expression of rat farnesyl:proteintransferase in Escherichia coli as a translationally coupled heterodimer. Protein Express. Purif. 14:395.

Hooff et al. (2008) Isoprenoid quantitation in human brain tissue: a validated HPLC–fluorescence detection method for endogenous farnesyl- (FPP) and geranylgeranylpyrophosphate (GGPP). Analytical and Bioanalytical Chemistry. 392 (4):673-680.

Watanabe et al. (2008) Inhibitors of Protein Geranylgeranyltransferase I and Rab Geranylgeranyltransferase Identified from a Library of Allenoate-derived Compounds. J. Biol. Chem. 283 (15):9571-9579.

Eckert et al. (2009) Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiology of Disease 35 (2):251-257.